Marshall Wace’s Sage Therapeutics SAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-1,147,571
| Closed | -$10.5M | – | 3338 |
|
|
2025
Q2 | $10.5M | Sell |
1,147,571
-614,101
| -35% | -$4.52M | 0.01% | 820 |
|
|
2025
Q1 | $14M | Buy |
+1,761,672
| New | +$12.9M | 0.02% | 642 |
|
|
2024
Q3 | – | Sell |
-108,439
| Closed | -$1.18M | – | 2902 |
|
|
2024
Q2 | $1.18M | Buy |
+108,439
| New | +$1.39M | ﹤0.01% | 1617 |
|
|
2023
Q4 | – | Sell |
-181,056
| Closed | -$3.73M | – | 2557 |
|
|
2023
Q3 | $3.73M | Sell |
181,056
-617,492
| -77% | -$17.8M | 0.01% | 981 |
|
|
2023
Q2 | $37.5M | Sell |
798,548
-613,381
| -43% | -$30.5M | 0.07% | 281 |
|
|
2023
Q1 | $59.2M | Buy |
1,411,929
+479,006
| +51% | +$20.6M | 0.13% | 177 |
|
|
2022
Q4 | $35.6M | Sell |
932,923
-69,737
| -7% | -$2.66M | 0.08% | 279 |
|
|
2022
Q3 | $39.3M | Sell |
1,002,660
-612,646
| -38% | -$23.7M | 0.09% | 260 |
|
|
2022
Q2 | $52.2M | Buy |
1,615,306
+981,273
| +155% | +$32.9M | 0.11% | 191 |
|
|
2022
Q1 | $21M | Buy |
634,033
+599,646
| +1,744% | +$22.5M | 0.04% | 477 |
|
|
2021
Q4 | $1.46M | Sell |
34,387
-44,834
| -57% | -$1.88M | ﹤0.01% | 2246 |
|
|
2021
Q3 | $3.51M | Buy |
+79,221
| New | +$3.63M | 0.01% | 1169 |
|
|
2021
Q1 | – | Sell |
-4,156
| Closed | -$360K | – | 2810 |
|
|
2020
Q4 | $360K | Sell |
4,156
-7,671
| -65% | -$565K | ﹤0.01% | 1601 |
|
|
2020
Q3 | $723K | Buy |
+11,827
| New | +$599K | ﹤0.01% | 1127 |
|
|
2020
Q2 | – | Sell |
-26,651
| Closed | -$765K | – | 1888 |
|
|
2020
Q1 | $765K | Buy |
26,651
+17,515
| +192% | +$1.01M | 0.01% | 877 |
|
|
2019
Q4 | $660K | Buy |
9,136
+6,834
| +297% | +$841K | ﹤0.01% | 1081 |
|
|
2019
Q3 | $323K | Sell |
2,302
-2,994
| -57% | -$501K | ﹤0.01% | 1188 |
|
|
2019
Q2 | $970K | Sell |
5,296
-17,549
| -77% | -$2.99M | 0.01% | 944 |
|
|
2019
Q1 | $3.63M | Sell |
22,845
-51,703
| -69% | -$7.49M | 0.03% | 561 |
|
|
2018
Q4 | $7.14M | Buy |
74,548
+7,372
| +11% | +$844K | 0.07% | 340 |
|
|
2018
Q3 | $9.49M | Sell |
67,176
-22,814
| -25% | -$3.52M | 0.08% | 312 |
|
|
2018
Q2 | $14.1M | Sell |
89,990
-101,407
| -53% | -$15.9M | 0.21% | 139 |
|
|
2018
Q1 | $30.8M | Buy |
191,397
+56,609
| +42% | +$9.61M | 1.28% | 14 |
|
|
2017
Q4 | $22.2M | Buy |
+134,788
| New | +$13.1M | 0.93% | 24 |
|
|
2017
Q2 | – | Sell |
-20,108
| Closed | -$1.43M | – | 380 |
|
|
2017
Q1 | $1.43M | Sell |
20,108
-289,979
| -94% | -$17M | 0.07% | 183 |
|
|
2016
Q4 | $15.8M | Sell |
310,087
-363,452
| -54% | -$17.1M | 0.1% | 234 |
|
|
2016
Q3 | $31M | Sell |
673,539
-17,426
| -3% | -$709K | 0.22% | 111 |
|
|
2016
Q2 | $20.8M | Buy |
690,965
+631,743
| +1,067% | +$21.1M | 0.18% | 145 |
|
|
2016
Q1 | $1.9M | Buy |
59,222
+27,148
| +85% | +$956K | 0.02% | 572 |
|
|
2015
Q4 | $1.87M | Buy |
+32,074
| New | +$1.59M | 0.02% | 582 |
|
Other funds holding SAGE
IA
HNB
Marshall Wace's SAGE Position: Q3 2025 in Review
Marshall Wace sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 1,147,571 shares — an estimated $10.5M sold.
Marshall Wace first reported a position in SAGE in Q4 2015 and held it in 30 quarters. The position peaked at $59.2M in Q1 2023. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.
- Marshall Wace reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
- Marshall Wace sold 1,147,571 Sage Therapeutics shares in Q3 2025, an estimated $10.5M.
- Marshall Wace first reported a position in Sage Therapeutics in Q4 2015 and held it in 30 quarters.
- Marshall Wace's Sage Therapeutics position peaked at $59.2M in Q1 2023.
- 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.
Based on Marshall Wace's 13F filing for Q3 2025, filed 13 Nov 2025.